OPRX analyst estimates
OptimizeRx (OPRX) analyst ratings, the average price target and its range, and every firm's latest call.
OPRX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 14, 2026 | UBS | OptimizeRX (OPRX) PT Raised to $11 at Citizens: Positioned for Return to Growth in 2027 | $11.00 |
| Aug 13, 2026 | Stifel Nicolaus | OptimizeRx price target lowered to $12 from $14 at Stifel | $12.00 |
| May 13, 2026 | Stifel Nicolaus | OptimizeRx price target lowered to $14 from $17 at Stifel | $14.00 |
| May 13, 2026 | Stephens | OptimizeRx price target lowered to $7 from $10 at Stephens | $7.00 |
| May 13, 2026 | Lake Street | OptimizeRx price target lowered to $11 from $20 at Lake Street | $11.00 |
| May 13, 2026 | UBS | OptimizeRx price target lowered to $10 from $11 at B. Riley | $10.00 |
| Mar 6, 2026 | Stifel Nicolaus | OptimizeRX (OPRX) PT Lowered to $17 at Stifel After Flattish Q4 Revenue | $17.00 |
| Oct 10, 2025 | UBS | OptimizeRx price target raised to $23 from $20 at Citizens JMP | $23.00 |
| Apr 4, 2024 | JMP Securities | JMP Securities Starts OptimizeRX (OPRX) at Market Outperform, 'Comprehensive Biopharma Digital Marketing Platform' | $15.00 |
- 6 firms rate OPRX: 5 buy, 1 hold, 0 sell.
- The average price target is $10.25 from None analysts, from $7.00 to $12.00.
Updated 2026-11-13 11:49 UTC